Rheumatoid arthritis (RA) is a progressive and painful systemic inflammatory disease that preferentially attacks the synovium of the joints and is associated with an extensive array of comorbidities. It affects approximately 1% of adults in the United States and, if left unchecked, leads to joint destruction, debility, and deformity. Physicians need to be better educated about newer treatment options for RA, such as the use of biosimilars, as well as better informed about the immunopathogenesis, treatment guidelines, and comorbidities associated with RA. In this educational activity, expert physicians will review such topics in a web-based format.
Upon successful completion of this educational activity, participants will be better able to:
- Examine the underlying immunopathology of RA and resulting implications for biomarker testing and treatment.
- Select treatment for patients with RA based on the latest clinical evidence and patient characteristics.
- Assess the benefits and limitations of biosimilars for management of RA.
- Implement best practices for the prevention of complications for patients with RA, including risk profiling and vaccination.
Author(s)/Faculty: Leonard H. Calabrese, DO; Allan Gibofsky, MD, JD, MACR, FACP, FCLM ; William F. C. Rigby, MD; Kevin Winthrop, MD, MPH
Source: Healio Rheumatology Education Lab
Release Date: 1/28/2019
Expiration Date: 1/27/2020
Credit Type: CME
Number of Credits: 1.5
Provider: Vindico Medical Education
Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
Support Statement: This activity is supported by an educational grant from Pfizer, Inc.
Target Audience: The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with RA.
Click here to view this activity.